 Moleculin Biotech Inc NASDAQ: MBRX has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, evaluating Annamycin for relapsed and refractory acute myeloid leukemia AML. Moleculin determined a dose of 240 mgm2 as the Recommended Phase 2 Dose RP2D, subject to final approval of the Safety Review Committee, and indicated no signs of cardiotoxicity. 